Search

Introduction: Allergic rhinitis, a chronic immunological disease, affects between 10% and 30% of the world's population, causing significant morbidity and disability, impacting quality of life, and accounting for 3% of medical visits. Objective: The goal was to improve the quality of life of students suffering from allergic rhinitis at the southern campus of ISTUL, levels I and II. Methods: An applied research study with a mixed-methods approach was conducted, utilizing both qualitative and quantitative methods with a cross-sectional design. The studied population consisted of 58 students, of whom 14 (24.1%) had rhinitis. The survey technique was employed, and a questionnaire was used as the instrument, with polytomous questions and a Likert scale for assessment. Results: Show that 70.2% of the participants had no family history of allergies. 18.97% reported frequent colds, with common symptoms such as nasal congestion (37.9%) and sneezing, with greater intensity during the night and morning. These findings underline the prevalence of respiratory and allergic symptoms, highlighting the need for management and prevention strategies. Conclusions: The prevalence of allergic rhinitis among students at the southern campus of ISTUL, levels I and II, underscores the need for continuous evaluation and appropriate treatment. Promoting healthy habits, reducing allergen exposure, and improving air quality are crucial measures to prevent the disease and enhance well-being and academic performance. Additionally, identifying allergens and environmental risk factors is essential for developing more effective management and prevention strategies. [ABSTRACT FROM AUTHOR]

The records of patients from the Allergology Service in the Previsora Policlinic, Camagüey were revised to evaluate benefits and risks of the subcutaneous immunotherapy (ITSC) with extracts of acari. The study was observational, analytic and retrospective of cases and controls in allergic rhinoconjunctivitis and bronchial asthma. A total of 160 subjects, older than 18 years old, were chosen. Eighty out of them had already received ITSC with dose increase during 13 weeks and maintenance with monthly injections during 18 months. A total of 80 patients who only received prevention measures and medications during the crises were paired. Questionnaires were applied for quality of rhinoconjunctivitis life and asthma, about the consumption of medications and the frequency of the crises. The adverse events were measured, as they were local and systemic to the cutaneous tests, to the ITSC and the different pharmacological treatments. There was a significant increase of the punctuation of life quality questionnaires, (p=0.011). The consumption of medications decreased in both the cases and the controls, without significant differences (p=0.083). The frequency of the rhinitis and asthma crises decrease in the group of ITSC (p=0.029). Slight local and systemic reactions were reported in both groups with Odds ratio (OR)=2.029 in the ITSC group, with a 95% confidence interval of 1.114-3.967 (p=0.019). The results show that the subcutaneous immunotherapy with acari offers benefits and few risks to patients with allergic rhinoconjunctivitis and asthma. [ABSTRACT FROM AUTHOR]